Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063803 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
A Phase 2 study, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
NCT01063803 is a Phase 2 study that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 266 participants.
The verdict
NCT01063803, a Phase 2 study, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
Study Summary
This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
Interventions
- DRUG ATN-103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063803
The ClinicalTrials.gov registry entry for NCT01063803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablynx, a Sanofi company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATN-103 is the first listed.
NCT01063803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063803 about?
NCT01063803 is a clinical study titled "Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis". This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
What is the current status of trial NCT01063803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2010-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01063803?
The interventions under investigation include: ATN-103 (DRUG).
Who is sponsoring clinical trial NCT01063803?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.